Targeting interferon-alpha to dendritic cells enhances a CD8 T cell response to a human CD40-targeted cancer vaccine.
- Citation data:
Vaccine, ISSN: 1873-2518, Vol: 35, Issue: 35 Pt B, Page: 4532-4539
- Publication Year:
- Repository URL:
- Biochemistry, Genetics and Molecular Biology; Immunology and Microbiology; Veterinary; Medicine; Life Sciences; Medicine and Health Sciences
- Most Recent Tweet View All Tweets
Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8 T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8 T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8 T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.